Akeso, Inc. ((HK:9926)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Akeso, Inc. is conducting a Phase III clinical study titled A Phase III, Randomized, Double-blinded, Multicenter Study of Cadonilimab (AK104) + Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma. The study aims to evaluate the effectiveness of combining AK104 and lenvatinib with TACE compared to TACE alone in treating patients with incurable, non-metastatic liver cancer.
The study tests an experimental treatment combining the drugs AK104 and lenvatinib with a procedure called transarterial chemoembolization (TACE). AK104 is administered intravenously, while lenvatinib is taken orally. TACE involves injecting chemotherapy and embolic agents into the hepatic artery.
This interventional study uses a randomized, parallel assignment model with quadruple masking to ensure unbiased results. The primary purpose is treatment, focusing on assessing the new combination’s efficacy against liver cancer.
The study began on April 15, 2024, with primary completion expected soon. The latest update was submitted on March 11, 2025, indicating ongoing recruitment and progress in the trial.
The outcome of this study could significantly impact Akeso’s market position and stock performance, especially if the combination treatment proves effective. It may also influence the competitive landscape in liver cancer treatment, affecting investor sentiment towards Akeso and its peers.
The study is currently ongoing, with more details available on the ClinicalTrials portal.